D. Small

发表

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

S. James, D. Erlinge, C. Varenhorst, 2014, Thrombosis and Haemostasis.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

K. Winters, J. Jakubowski, J. Brandt, 2008, Thrombosis and Haemostasis.

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

J. Suico, D. Small, J. Royalty, 2016, European Journal of Clinical Pharmacology.

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin

B. Zhu, D. Small, Christine Y. Yu, 2012, Current medical research and opinion.

Prasugrel in Children With Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Data From an Open-label, Adaptive-design, Dose-ranging Study

K. Winters, C. Quinn, M. Heeney, 2015, Journal of pediatric hematology/oncology.

Pharmacokinetic and Pharmacodynamic Effects of Prasugrel in Healthy Korean Males

Kyung-Woo Park, K. Yu, R. Kelly, 2013, Journal of cardiovascular pharmacology.

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.

D. Foley, Junxiang Luo, S. James, 2012, Journal of the American College of Cardiology.

Pharmacokinetics, pharmacodynamics and drug interactions of evacetrapib with select statins in healthy Chinese subjects

J. Suico, Xia Zhao, Yi-min Cui, 2018 .

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects

J. Suico, D. Small, J. Royalty, 2016, Pharmacotherapy.

Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model

N. Vélez de Mendizábal, D. Small, Lisa Ferguson-Sells, 2021, Clinical Pharmacokinetics.

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

E. Antman, E. Braunwald, S. Wiviott, 2009, Journal of clinical pharmacology.

Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation

V. Fuster, J. Badimón, C. Giannarelli, 2013, Journal of thrombosis and haemostasis : JTH.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

R. Kelly, K. Winters, P. Kothare, 2010, Clinical therapeutics.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

K. Winters, P. Kothare, J. Jakubowski, 2010, European Journal of Clinical Pharmacology.

Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

K. Winters, S. Rohatagi, D. Small, 2010, Journal of clinical pharmacology.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

L. Wallentin, K. Winters, C. Ernest, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease

K. Winters, R. Wrishko, J. Brandt, 2009, Journal of clinical pharmacy and therapeutics.

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

K. Winters, C. Ernest, J. Jakubowski, 2008, Pharmacotherapy.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

K. Winters, C. Ernest, N. Farid, 2009, Journal of clinical pharmacy and therapeutics.

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

J. Suico, S. Friedrich, P. Yi, 2015, Pharmacology research & perspectives.

Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia

J. Jakubowski, D. Small, B. Moser, 2018, Clinical Pharmacokinetics.

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

D. Erlinge, D. Alexopoulos, D. Angiolillo, 2017, American Journal of Cardiovascular Drugs.

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

S. James, D. Erlinge, D. Angiolillo, 2013, Journal of Thrombosis and Thrombolysis.

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.

T. Lindahl, D. Foley, Junxiang Luo, 2013, Journal of the American College of Cardiology.

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

Junxiang Luo, C. Ernest, R. Wrishko, 2012, Journal of clinical pharmacology.

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

K. Winters, C. Ernest, N. Farid, 2011, Journal of clinical pharmacology.

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

E. Antman, S. Wiviott, C. Ernest, 2008 .

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

K. Winters, C. Ernest, N. Farid, 2008, Journal of clinical pharmacology.

The Effect of Cyp2c19 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Prasugrel 5-mg, Prasugrel 10-mg and Clopidogrel 75-mg in Patients with Coronary Artery Disease Gurbel Cyp2c19 Genetics in Generations and Feather

T. Lindahl, S. James, D. Erlinge, 2022 .

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing

K. Winters, C. Ernest, R. Wrishko, 2009, Drugs & aging.

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

K. Winters, J. Jakubowski, J. Brandt, 2008, Platelets.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

K. Winters, C. Ernest, J. Jakubowski, 2009, Current medical research and opinion.

The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data

M. Effron, P. Kulkarni, Junxiang Luo, 2011, Journal of cardiovascular pharmacology.

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis

Junxiang Luo, K. Winters, J. Jakubowski, 2010, Journal of cardiovascular pharmacology.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

K. Winters, J. Jakubowski, J. Brandt, 2007, Thrombosis and Haemostasis.

Obesity Does Not Alter the Pharmacokinetics of Drotrecogin Alfa (Activated) in Severe Sepsis

R. Riker, J. Steingrub, D. Small, 2005, The Annals of pharmacotherapy.

Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

J. Helterbrand, J. Dhainaut, M. Seger, 2002, Clinical pharmacology and therapeutics.

A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

K. Winters, A. Frelinger, S. Jurcevic, 2013, British journal of clinical pharmacology.

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

Brendan E. Smith, M. Heeney, D. Rees, 2016, Thrombosis and Haemostasis.

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

S. Friedrich, S. Hall, A. Ke, 2015, Journal of clinical pharmacology.

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study

N. Dahdah, D. Bonnet, D. Small, 2019, British journal of clinical pharmacology.

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascendingdose study

Sells, N. Dahdah, D. Bonnet, 2019 .

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2006, Journal of cardiovascular pharmacology.

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

K. Winters, J. Jakubowski, Y. Li, 2011, Thrombosis and Haemostasis.

Comment: obese man treated with drotrecogin alfa (activated)

D. Small, H. Levy, 2004, The Annals of pharmacotherapy.

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

J. Suico, D. Small, J. Royalty, 2016, European Journal of Clinical Pharmacology.

Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]‐evacetrapib as a tracer

J. Suico, B. Pack, K. Ruterbories, 2015, Journal of labelled compounds & radiopharmaceuticals.

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

K. Winters, Lei-Bin Shen, R. Kelly, 2012, British journal of clinical pharmacology.

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

K. Winters, G. Weerakkody, J. Brandt, 2008, Journal of clinical pharmacology.

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State

J. Suico, S. Friedrich, D. Small, 2015, Journal of cardiovascular pharmacology and therapeutics.

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

R. Brilli, T. Yeh, B. Giroir, 2004, Pediatrics.

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

K. Winters, C. Ernest, J. Jakubowski, 2007, Clinical pharmacology and therapeutics.

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

K. Winters, C. Ernest, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

K. Winters, S. Wiviott, G. Weerakkody, 2007, American heart journal.

Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel

K. Winters, J. Jakubowski, N. Farid, 2010, Clinical pharmacokinetics.

The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

S. James, D. Erlinge, D. Angiolillo, 2014, Thrombosis research.

AS-248: Prasugrel and Clopidogrel in Chinese CYP2C19 Allelic Variants following Maintenance Doses

R. Kelly, Lei-Bin Shen, J. Jakubowski, 2009 .

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

K. Winters, N. Farid, Y. Li, 2008, Current medical research and opinion.

Amount of Testosterone on Laundered Clothing After Use of Testosterone Topical 2% Solution by Healthy Male Volunteers.

M. Mitchell, D. Small, D. Muram, 2016, Journal of Sexual Medicine.

Effect of deodorant and antiperspirant use and presence or absence of axillary hair on absorption of testosterone 2% solution applied to men's axillae.

M. Mitchell, D. Small, D. Satonin, 2014, The journal of sexual medicine.

Steady-State Pharmacokinetics of Darunavir/Ritonavir and Pitavastatin when Co-administered to Healthy Adult Volunteers

D. Small, Christine Y. Yu, Stuart E. Campbell, 2014, Clinical Drug Investigation.

Pharmacokinetic evaluation of combined duloxetine and fluvoxamine dosing in CYP2D6 poor metabolizers

R. Bergstrom, J. Callaghan, D. Small, 2005 .

QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of duloxetine at supratherapeutic doses

J. Callaghan, D. Small, J. Chappell, 2005 .

QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study

L. Ereshefsky, D. Desaiah, D. Hoelscher, 2007, Journal of cardiovascular pharmacology.

Let's abolish ‘fold higher’ and ‘fold increase’ from our lexicon

D. Small, 2016 .

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

T. Lindahl, S. James, D. Erlinge, 2014, Thrombosis and Haemostasis.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease

K. Winters, C. Ernest, R. Wrishko, 2009, Journal of clinical pharmacy and therapeutics.

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

T. Lindahl, D. Foley, Junxiang Luo, 2013, Journal of the American College of Cardiology.